The Cancer Monoclonal Antibody Partnering Terms and Agreements report
provides comprehensive understanding and unprecedented access to the cancer
monoclonal antibody partnering deals and agreements entered into by the worlds
leading healthcare companies.
Description
The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal
trends, players, financials and forecasts report provides an understanding and
access to the cancer monoclonal antibody partnering deals and agreements
entered into by the worlds leading healthcare companies.
Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of
development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value
The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal
trends, players, financials and forecasts report provides an understanding and
access to the cancer monoclonal antibody partnering deals and agreements
entered into by the worlds leading healthcare companies.
The report provides an understanding and analysis of how and why
companies enter cancer monoclonal antibody partnering deals. The majority of
deals are discovery stage whereby the licensee obtains a right or an option
right to license the licensors monoclonal antibody technology. These deals tend
to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in terms of
what you can expect to achieve during the negotiation of terms. Whilst many
smaller companies will be seeking details of the payments clauses, the devil is
in the detail in terms of how payments are triggered – contract documents provide
this insight where press releases do not.
This report contains over 250 links to online copies of actual cancer
monoclonal antibody deals and where available, contract documents as submitted
to the Securities Exchange Commission by companies and their partners. Contract
documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will
have a significant impact on each party’s ability to derive value from the
deal.
The initial chapters of the report provide an orientation of cancer
monoclonal dealmaking and its associated business and partnering activities.
This chapter provides an overall introduction to the report and what you will
learn from it, whilst chapter 2 provides an overview of the trends in cancer
monoclonal antibody deal making since 2010, categorizing by deal type, industry
sector, stage of development and technology type.
A popular chapter with readers chapter 3 covers the average financial
deal terms for deals signed in the cancer monoclonal antibody field with a
stage of development announced. Deals are listed and sectioned by average
headlines, upfront payments, milestone payments and royalty rates. The median
values of these deals are then presented by stage of development at signing.
Numerous tables and figures are weaved within the report to support
the findings and illustrate the trends and activities in cancer monoclonal
antibody partnering and dealmaking since 2010.
Chapter 4 covers the leading cancer monoclonal antibody deals that
have been announced over the past five years. Deals are listed by headline
value. Where the deal has an agreement contract published at the SEC a link
provides online access to the contract. Full deal contract documents where
available for each deal are indicated by a yes/no symbol. Within this chapter
the most active cancer monoclonal antibody deal makers are also listed as well
as the deal making activities and the number of deals entered into by the big
pharma and biotech companies.
Chapter 5 acts as a contracts reference directory chapter providing a
full comprehensive and detailed list of the Cancer monoclonal antibody
partnering deals signed and announced since January 2010. This chapter is
organized by company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc), and therapy focus. In
order for readers to view full details of each agreement the report is
formatted so that each deal title links via Weblink to an online version of the
actual deal at Current Agreements deals and alliances database.
Chapter 6 brings the report to a conclusion by looking ahead to the
future of cancer monoclonal antibody partnering. Newly introduced to provide
readers with potential prospects and partnering insights this chapter selects
emerging companies to watch in 2015 and details their recent deal making and
financial activities. These companies could be potential targets for those who
want to invest or partner in the coming months.
In conclusion, this report gives prospective dealmakers a thorough
overview of all the deals announced in the cancer monoclonal antibody field
preparing them with everything they need to know about partnering in the
research, development and commercialization of cancer monoclonal antibody
technologies and products.
A full appendix is provided at the very end of the report which lists
all the cancer monoclonal antibody deals announced since 2010 categorized by
company A-Z, deal type, stage of development, technology and therapy. Where
available contract documents are supplied, these documents include additional
deal information in comparison to only the brief summary that is provided
through a press release. Readers can analyze the contracts fully by reviewing the
detailed terms between the parties under which monies and licensing rights are
exchanged. The appendix is useful for looking at all the deals signed by one
specific company.
Report scope
Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends,
players, financials and forecasts is intended to provide the reader with an
in-depth understanding and access to cancer monoclonal antibody trends and
structure of deals entered into by leading companies worldwide.
Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends,
players, financials and forecasts includes:
Trends in cancer monoclonal antibody dealmaking in the biopharma
industry since 2009
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 250 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2009
In Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal
trends, players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific oncology therapy target
- Monoclonal antibody type
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access to
each contract document on demand.
The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal
trends, players, financials and forecasts report provides comprehensive access
to available deals and contract documents for over 250 cancer monoclonal
antibody deals. Analyzing actual contract agreements allows assessment of the
following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends,
players, financials and forecasts provides the reader with the following key
benefits:
- In-depth understanding of cancer monoclonal antibody deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Acces to the structure of cancer monoclonal antibody agreements with numerous real life case studies
- Comprehensive access to over 250 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
- Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 659 pages, “Global
Cancer Monoclonal Antibody Partnering 2010-2015: Deal Trends, players,
financials and forecasts” report covers the Executive Summary,
Introduction, Trends in cancer monoclonal antibody dealmaking, Average
financial deal terms for cancer monoclonal antibody partnering, Leading cancer
monoclonal antibody deals, Cancer monoclonal antibody contracts directory, Future
trends and companies in cancer monoclonal antibody deal making, Partnering
resource centre, Appendices.
For
further information on this report, please visit- http://mrr.cm/4Q4
Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology
No comments:
Post a Comment
Note: only a member of this blog may post a comment.